table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2022-2027)
1.4.2 East Asia Market States and Outlook (2022-2027)
1.4.3 Europe Market States and Outlook (2022-2027)
1.4.4 South Asia Market States and Outlook (2022-2027)
1.4.5 Southeast Asia Market States and Outlook (2022-2027)
1.4.6 Middle East Market States and Outlook (2022-2027)
1.4.7 Africa Market States and Outlook (2022-2027)
1.4.8 Oceania Market States and Outlook (2022-2027)
1.4.9 South America Market States and Outlook (2022-2027)
1.5 Global Neurological Disorder Drugs Market Size Analysis from 2022 to 2027
1.5.1 Global Neurological Disorder Drugs Market Size Analysis from 2022 to 2027 by Consumption Volume
1.5.2 Global Neurological Disorder Drugs Market Size Analysis from 2022 to 2027 by Value
1.5.3 Global Neurological Disorder Drugs Price Trends Analysis from 2022 to 2027
1.6 COVID-19 Outbreak: Neurological Disorder Drugs Industry Impact
Chapter 2 Global Neurological Disorder Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Neurological Disorder Drugs (Volume and Value) by Type
2.1.1 Global Neurological Disorder Drugs Consumption and Market Share by Type (2016-2021)
2.1.2 Global Neurological Disorder Drugs Revenue and Market Share by Type (2016-2021)
2.2 Global Neurological Disorder Drugs (Volume and Value) by Application
2.2.1 Global Neurological Disorder Drugs Consumption and Market Share by Application (2016-2021)
2.2.2 Global Neurological Disorder Drugs Revenue and Market Share by Application (2016-2021)
2.3 Global Neurological Disorder Drugs (Volume and Value) by Regions
2.3.1 Global Neurological Disorder Drugs Consumption and Market Share by Regions (2016-2021)
2.3.2 Global Neurological Disorder Drugs Revenue and Market Share by Regions (2016-2021)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2016-2021 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2016-2021 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Neurological Disorder Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
4.1 Global Neurological Disorder Drugs Consumption by Regions (2016-2021)
4.2 North America Neurological Disorder Drugs Sales, Consumption, Export, Import (2016-2021)
4.3 East Asia Neurological Disorder Drugs Sales, Consumption, Export, Import (2016-2021)
4.4 Europe Neurological Disorder Drugs Sales, Consumption, Export, Import (2016-2021)
4.5 South Asia Neurological Disorder Drugs Sales, Consumption, Export, Import (2016-2021)
4.6 Southeast Asia Neurological Disorder Drugs Sales, Consumption, Export, Import (2016-2021)
4.7 Middle East Neurological Disorder Drugs Sales, Consumption, Export, Import (2016-2021)
4.8 Africa Neurological Disorder Drugs Sales, Consumption, Export, Import (2016-2021)
4.9 Oceania Neurological Disorder Drugs Sales, Consumption, Export, Import (2016-2021)
4.10 South America Neurological Disorder Drugs Sales, Consumption, Export, Import (2016-2021)
Chapter 5 North America Neurological Disorder Drugs Market Analysis
5.1 North America Neurological Disorder Drugs Consumption and Value Analysis
5.1.1 North America Neurological Disorder Drugs Market Under COVID-19
5.2 North America Neurological Disorder Drugs Consumption Volume by Types
5.3 North America Neurological Disorder Drugs Consumption Structure by Application
5.4 North America Neurological Disorder Drugs Consumption by Top Countries
5.4.1 United States Neurological Disorder Drugs Consumption Volume from 2016 to 2021
5.4.2 Canada Neurological Disorder Drugs Consumption Volume from 2016 to 2021
5.4.3 Mexico Neurological Disorder Drugs Consumption Volume from 2016 to 2021
Chapter 6 East Asia Neurological Disorder Drugs Market Analysis
6.1 East Asia Neurological Disorder Drugs Consumption and Value Analysis
6.1.1 East Asia Neurological Disorder Drugs Market Under COVID-19
6.2 East Asia Neurological Disorder Drugs Consumption Volume by Types
6.3 East Asia Neurological Disorder Drugs Consumption Structure by Application
6.4 East Asia Neurological Disorder Drugs Consumption by Top Countries
6.4.1 China Neurological Disorder Drugs Consumption Volume from 2016 to 2021
6.4.2 Japan Neurological Disorder Drugs Consumption Volume from 2016 to 2021
6.4.3 South Korea Neurological Disorder Drugs Consumption Volume from 2016 to 2021
Chapter 7 Europe Neurological Disorder Drugs Market Analysis
7.1 Europe Neurological Disorder Drugs Consumption and Value Analysis
7.1.1 Europe Neurological Disorder Drugs Market Under COVID-19
7.2 Europe Neurological Disorder Drugs Consumption Volume by Types
7.3 Europe Neurological Disorder Drugs Consumption Structure by Application
7.4 Europe Neurological Disorder Drugs Consumption by Top Countries
7.4.1 Germany Neurological Disorder Drugs Consumption Volume from 2016 to 2021
7.4.2 UK Neurological Disorder Drugs Consumption Volume from 2016 to 2021
7.4.3 France Neurological Disorder Drugs Consumption Volume from 2016 to 2021
7.4.4 Italy Neurological Disorder Drugs Consumption Volume from 2016 to 2021
7.4.5 Russia Neurological Disorder Drugs Consumption Volume from 2016 to 2021
7.4.6 Spain Neurological Disorder Drugs Consumption Volume from 2016 to 2021
7.4.7 Netherlands Neurological Disorder Drugs Consumption Volume from 2016 to 2021
7.4.8 Switzerland Neurological Disorder Drugs Consumption Volume from 2016 to 2021
7.4.9 Poland Neurological Disorder Drugs Consumption Volume from 2016 to 2021
Chapter 8 South Asia Neurological Disorder Drugs Market Analysis
8.1 South Asia Neurological Disorder Drugs Consumption and Value Analysis
8.1.1 South Asia Neurological Disorder Drugs Market Under COVID-19
8.2 South Asia Neurological Disorder Drugs Consumption Volume by Types
8.3 South Asia Neurological Disorder Drugs Consumption Structure by Application
8.4 South Asia Neurological Disorder Drugs Consumption by Top Countries
8.4.1 India Neurological Disorder Drugs Consumption Volume from 2016 to 2021
8.4.2 Pakistan Neurological Disorder Drugs Consumption Volume from 2016 to 2021
8.4.3 Bangladesh Neurological Disorder Drugs Consumption Volume from 2016 to 2021
Chapter 9 Southeast Asia Neurological Disorder Drugs Market Analysis
9.1 Southeast Asia Neurological Disorder Drugs Consumption and Value Analysis
9.1.1 Southeast Asia Neurological Disorder Drugs Market Under COVID-19
9.2 Southeast Asia Neurological Disorder Drugs Consumption Volume by Types
9.3 Southeast Asia Neurological Disorder Drugs Consumption Structure by Application
9.4 Southeast Asia Neurological Disorder Drugs Consumption by Top Countries
9.4.1 Indonesia Neurological Disorder Drugs Consumption Volume from 2016 to 2021
9.4.2 Thailand Neurological Disorder Drugs Consumption Volume from 2016 to 2021
9.4.3 Singapore Neurological Disorder Drugs Consumption Volume from 2016 to 2021
9.4.4 Malaysia Neurological Disorder Drugs Consumption Volume from 2016 to 2021
9.4.5 Philippines Neurological Disorder Drugs Consumption Volume from 2016 to 2021
9.4.6 Vietnam Neurological Disorder Drugs Consumption Volume from 2016 to 2021
9.4.7 Myanmar Neurological Disorder Drugs Consumption Volume from 2016 to 2021
Chapter 10 Middle East Neurological Disorder Drugs Market Analysis
10.1 Middle East Neurological Disorder Drugs Consumption and Value Analysis
10.1.1 Middle East Neurological Disorder Drugs Market Under COVID-19
10.2 Middle East Neurological Disorder Drugs Consumption Volume by Types
10.3 Middle East Neurological Disorder Drugs Consumption Structure by Application
10.4 Middle East Neurological Disorder Drugs Consumption by Top Countries
10.4.1 Turkey Neurological Disorder Drugs Consumption Volume from 2016 to 2021
10.4.2 Saudi Arabia Neurological Disorder Drugs Consumption Volume from 2016 to 2021
10.4.3 Iran Neurological Disorder Drugs Consumption Volume from 2016 to 2021
10.4.4 United Arab Emirates Neurological Disorder Drugs Consumption Volume from 2016 to 2021
10.4.5 Israel Neurological Disorder Drugs Consumption Volume from 2016 to 2021
10.4.6 Iraq Neurological Disorder Drugs Consumption Volume from 2016 to 2021
10.4.7 Qatar Neurological Disorder Drugs Consumption Volume from 2016 to 2021
10.4.8 Kuwait Neurological Disorder Drugs Consumption Volume from 2016 to 2021
10.4.9 Oman Neurological Disorder Drugs Consumption Volume from 2016 to 2021
Chapter 11 Africa Neurological Disorder Drugs Market Analysis
11.1 Africa Neurological Disorder Drugs Consumption and Value Analysis
11.1.1 Africa Neurological Disorder Drugs Market Under COVID-19
11.2 Africa Neurological Disorder Drugs Consumption Volume by Types
11.3 Africa Neurological Disorder Drugs Consumption Structure by Application
11.4 Africa Neurological Disorder Drugs Consumption by Top Countries
11.4.1 Nigeria Neurological Disorder Drugs Consumption Volume from 2016 to 2021
11.4.2 South Africa Neurological Disorder Drugs Consumption Volume from 2016 to 2021
11.4.3 Egypt Neurological Disorder Drugs Consumption Volume from 2016 to 2021
11.4.4 Algeria Neurological Disorder Drugs Consumption Volume from 2016 to 2021
11.4.5 Morocco Neurological Disorder Drugs Consumption Volume from 2016 to 2021
Chapter 12 Oceania Neurological Disorder Drugs Market Analysis
12.1 Oceania Neurological Disorder Drugs Consumption and Value Analysis
12.2 Oceania Neurological Disorder Drugs Consumption Volume by Types
12.3 Oceania Neurological Disorder Drugs Consumption Structure by Application
12.4 Oceania Neurological Disorder Drugs Consumption by Top Countries
12.4.1 Australia Neurological Disorder Drugs Consumption Volume from 2016 to 2021
12.4.2 New Zealand Neurological Disorder Drugs Consumption Volume from 2016 to 2021
Chapter 13 South America Neurological Disorder Drugs Market Analysis
13.1 South America Neurological Disorder Drugs Consumption and Value Analysis
13.1.1 South America Neurological Disorder Drugs Market Under COVID-19
13.2 South America Neurological Disorder Drugs Consumption Volume by Types
13.3 South America Neurological Disorder Drugs Consumption Structure by Application
13.4 South America Neurological Disorder Drugs Consumption Volume by Major Countries
13.4.1 Brazil Neurological Disorder Drugs Consumption Volume from 2016 to 2021
13.4.2 Argentina Neurological Disorder Drugs Consumption Volume from 2016 to 2021
13.4.3 Columbia Neurological Disorder Drugs Consumption Volume from 2016 to 2021
13.4.4 Chile Neurological Disorder Drugs Consumption Volume from 2016 to 2021
13.4.5 Venezuela Neurological Disorder Drugs Consumption Volume from 2016 to 2021
13.4.6 Peru Neurological Disorder Drugs Consumption Volume from 2016 to 2021
13.4.7 Puerto Rico Neurological Disorder Drugs Consumption Volume from 2016 to 2021
13.4.8 Ecuador Neurological Disorder Drugs Consumption Volume from 2016 to 2021
Chapter 14 Company Profiles and Key Figures in Neurological Disorder Drugs Business
14.1 Novartis AG
14.1.1 Novartis AG Company Profile
14.1.2 Novartis AG Neurological Disorder Drugs Product Specification
14.1.3 Novartis AG Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.2 GlaxoSmithKline plc
14.2.1 GlaxoSmithKline plc Company Profile
14.2.2 GlaxoSmithKline plc Neurological Disorder Drugs Product Specification
14.2.3 GlaxoSmithKline plc Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.3 Merck & Co.
14.3.1 Merck & Co. Company Profile
14.3.2 Merck & Co. Neurological Disorder Drugs Product Specification
14.3.3 Merck & Co. Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.4 Bayer AG
14.4.1 Bayer AG Company Profile
14.4.2 Bayer AG Neurological Disorder Drugs Product Specification
14.4.3 Bayer AG Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.5 AstraZeneca
14.5.1 AstraZeneca Company Profile
14.5.2 AstraZeneca Neurological Disorder Drugs Product Specification
14.5.3 AstraZeneca Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.6 Boehringer Ingelheim GmbH
14.6.1 Boehringer Ingelheim GmbH Company Profile
14.6.2 Boehringer Ingelheim GmbH Neurological Disorder Drugs Product Specification
14.6.3 Boehringer Ingelheim GmbH Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.7 Teva Pharmaceutical
14.7.1 Teva Pharmaceutical Company Profile
14.7.2 Teva Pharmaceutical Neurological Disorder Drugs Product Specification
14.7.3 Teva Pharmaceutical Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
Chapter 15 Global Neurological Disorder Drugs Market Forecast (2022-2027)
15.1 Global Neurological Disorder Drugs Consumption Volume, Revenue and Price Forecast (2022-2027)
15.1.1 Global Neurological Disorder Drugs Consumption Volume and Growth Rate Forecast (2022-2027)
15.1.2 Global Neurological Disorder Drugs Value and Growth Rate Forecast (2022-2027)
15.2 Global Neurological Disorder Drugs Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)
15.2.1 Global Neurological Disorder Drugs Consumption Volume and Growth Rate Forecast by Regions (2022-2027)
15.2.2 Global Neurological Disorder Drugs Value and Growth Rate Forecast by Regions (2022-2027)
15.2.3 North America Neurological Disorder Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.4 East Asia Neurological Disorder Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.5 Europe Neurological Disorder Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.6 South Asia Neurological Disorder Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.7 Southeast Asia Neurological Disorder Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.8 Middle East Neurological Disorder Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.9 Africa Neurological Disorder Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.10 Oceania Neurological Disorder Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.11 South America Neurological Disorder Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.3 Global Neurological Disorder Drugs Consumption Volume, Revenue and Price Forecast by Type (2022-2027)
15.3.1 Global Neurological Disorder Drugs Consumption Forecast by Type (2022-2027)
15.3.2 Global Neurological Disorder Drugs Revenue Forecast by Type (2022-2027)
15.3.3 Global Neurological Disorder Drugs Price Forecast by Type (2022-2027)
15.4 Global Neurological Disorder Drugs Consumption Volume Forecast by Application (2022-2027)
15.5 Neurological Disorder Drugs Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
